American Gene Technologies Appoints Dr. Drew Palin as CEO Business and Strategic Advisor | News
ROCKVILLE, MD., January 5, 2022 / PRNewswire-PRWeb / – American Genetic technologies (AGT) announces the appointment of Dr. Drew palin as a commercial and strategic advisor to Jeff galvin, CEO.
“I am delighted to have Drew officially on board. He has been advising me informally for some time now, and he is an invaluable addition to the team,” said the CEO Jeff galvin. “Drew’s extensive medical and business background combined with his unique sense of entrepreneurship will dramatically accelerate AGT’s mission.”
Dr Palin is a bold healthcare entrepreneur with rare expertise spanning clinical medicine, information technology and medical devices. During his career, Dr. Palin raised $ 20 million to fund new entities and generate multi-million dollar revenue, selling new products based on vision, personal integrity and trust. In addition to his role at AGT, Dr Palin has been the founding CEO, medical director and innovation director of several start-ups, including Intellivisit, an AI-based clinical diagnostic platform based in Milwaukee, Wisconsin.
“My entire career has been spent at the crossroads of medicine and technology. I have been a doctor, entrepreneur and CEO. I am delighted to help AGT be successful in any way possible, ”said Dr. Palin. “AGT has over a decade of creative discoveries, development, patents and clinical work by scientists and businessmen that have resulted in a platform that is poised to have measurable human impact. in millions of patients currently living with HIV. There are a lot of genes and cell therapy companies doing amazing work approving drugs for previously fatal or incurable diseases, but I think AGT will be one of the first companies to come up with a component-based platform. which creates new efficiency and greater competition in the pharmaceutical market. “
Dr. Palin’s experience as a business leader, investor and entrepreneur will be an important asset to AGT’s mission as AGT moves forward with its Phase 1 clinical trial of AGT103-T , a curative cell and gene therapy for HIV. Dr. Palin will advise the CEO of AGT on a wide variety of business, operational, governance and marketing strategies to maximize the chances of success in human trials and to bring new solutions to patients.
Phase 1 in the Maryland/ DC Zone
AGT’s Phase 1 trial for AGT103-T is currently underway at trial sites in the Maryland / Washington DC region. The recruitment status of phase 1 Repair (Restore Potent Antiviral Immune Responses) as well as information on trial sites are available at ClinicalTrials.gov. The trial is the company’s first step in clinical trials of cell and gene therapy for HIV, cancer and rare diseases.
According to UNAIDS, approximately 37.7 million people worldwide are living with HIV / AIDS. In the United States, government statistics show that 1.2 million people have HIV and estimate that 34,800 Americans were newly infected with HIV in 2019. Globally, UNAIDS estimates that approximately 1.5 million people have been infected with HIV. newly infected with HIV in 2020. Washington DC/Baltimore region is often cited as a “hot spot” for HIV, with Washington DC, having the highest infection rate at nearly 46 cases per 100,000 population and City of Baltimore having rates of 17 cases per 100,000. Maryland also ranks sixth among U.S. states and territories for HIV diagnosis rates, with more than 900 new cases in 2019 alone, according to the Maryland Department of Health.
Since the late 1980s, antiretroviral drugs have restored the quality of life for people living with HIV and in some cases have even been used to prevent new infections. However, no approved treatment has demonstrated the ability to cure HIV. AGT is committed to meeting this unmet medical need.
AGT103-T is a genetically modified cellular product made from a person’s own cells. AGT’s unique approach focuses on repairing major damage to the immune system caused by HIV. AGT’s goal is to develop cell and gene therapy capable of repairing the immune system in order to ensure natural control of HIV replication.
About American Genetic technologies
AGT is a gene and cell therapy company with a proprietary gene delivery platform for the rapid development of cell and gene therapies aimed at curing infectious diseases, cancers and inherited disorders. AGT’s mission is to transform people’s lives with genetic drugs that rid the body of disease. AGT has obtained four patents for the technology used to manufacture the AGT103-T and 11 patents for its unique immuno-oncological approach stimulate gamma-delta (γδ) T lymphocytes to destroy a variety of solid tumors. The company has developed a synthetic gene for the treatment Phenylketonuria (PKU), a crippling inherited disease. AGT treatment for PKU has been granted Orphan drug designation by the Food and Drug Administration (FDA), and it is expected to reach the clinic in 2022.
Kathy fowler, American Genetic technologies, 410-963-2345, [email protected]
SOURCE American Genetic technologies